Tumor News and Research

RSS

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

New research from the University of Alabama at Birmingham casts doubt on the long-standing belief that the vaccine for shingles should not be given to patients taking biologics for auto-immune diseases such as rheumatoid arthritis.

4 Jul 2012

Tolfenamic acid appears to reduce esophageal tumors

A new study by researchers at MD Anderson Cancer Center Orlando finds that Tolfenamic acid (TA), a non-steroidal anti-inflammatory drug (NSAID), commonly used to relieve pain, inflammation and migraines has now been found to reduce esophageal tumors.

4 Jul 2012

EMR improves physicians' compliance with portal image review

The use of an electronic medical record (EMR) for reviewing portal images dramatically improves compliance with timeliness and record keeping, according to a study in the July issue of the Journal of the American College of Radiology.

3 Jul 2012

New method promotes selection and growth of dangerous cancer cells

The news a cancer patient most fears is that the disease has spread and become much more difficult to treat. A new method to isolate and grow the most dangerous cancer cells could enable new research into how cancer spreads and, ultimately, how to fight it.

3 Jul 2012

Study confirms a rare susceptibility variant in glioma

Researchers at Moffitt Cancer Center working with colleagues at three other institutions have validated a link between a rare genetic variant and the risk of glioma, the most common and lethal type of brain tumor.

3 Jul 2012

Imaging PR status may help identify tumor response to endocrine therapy

Research published in the July issue of The Journal of Nuclear Medicine shows imaging progesterone receptor (PR) status also may be able to identify responders and nonresponders to endocrine therapy at an early stage.

3 Jul 2012

Study demonstrates effectiveness of combination therapy for breast cancer cells in vitro

A study conducted at Boston University School of Medicine (BUSM) demonstrates an effective combination therapy for breast cancer cells in vitro.

3 Jul 2012

Caffeinated coffee intake may reduce risk of basal cell carcinoma

Increasing the number of cups of caffeinated coffee you drink could lower your risk of developing the most common form of skin cancer, basal cell carcinoma, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

3 Jul 2012

DKK1 boosts liver cancer diagnostic options

Measurement of the protein Dickkopf-1 in serum could be used to diagnose hepatocellular carcinoma, especially early disease, Chinese researchers report.

2 Jul 2012

Routine use of pelvic CT scans in Wilms tumor questioned

Omitting pelvic computed tomography scans from the routine surveillance of off-therapy patients with Wilms tumor could reduce radiation exposure without compromising relapse detection rates, researchers report.

2 Jul 2012

Platelet activation linked to osteoporosis

Elderly, postmenopausal women with osteoporosis have elevated platelet volumes, report researchers.

2 Jul 2012

Study investigates association between SCC and cutaneous HPV types belonging to five different genera

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida, the German Cancer Research Center in Heidelberg, and the International Agency for Research on Cancer in Lyon, France, conducted a case control study and found associations between having antibodies to certain types of cutaneous human papillomavirus (HPV) and a kind of skin cancer called squamous cell carcinoma (SCC).

2 Jul 2012

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer.

2 Jul 2012

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.

2 Jul 2012

Rexahn submits RX-5902 IND to FDA for treatment of advanced or metastatic solid tumors

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors.

2 Jul 2012

CytRx granted European patent for tumor-targeting linker platform technology

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company's tumor-targeting linker platform technology and pharmaceutical compositions.

2 Jul 2012

Safer alternative to experimental gene therapy against HIV infection

Scientists at The Scripps Research Institute have discovered a surprisingly simple and safe method to disrupt specific genes within cells. The scientists highlighted the medical potential of the new technique by demonstrating its use as a safer alternative to an experimental gene therapy against HIV infection.

2 Jul 2012

New treatment target against metastatic pancreatic cancer

Detailed analysis of genes expressed in circulating tumor cells (CTCs) -- cells that break off from solid tumors and travel through the bloodstream -- has identified a potential treatment target in metastatic pancreatic cancer.

2 Jul 2012

New volumetric functional MRI scan figures out beneficiaries of chemotherapy in liver cancer patients

Studies on some 55 U.S. men and women with potentially deadly liver or pancreatic cancers show that specialized MRI scans can tell within a month whether highly toxic chemotherapy is working and killing tumor cells long before tumors actually shrink - or fail to shrink.

2 Jul 2012

Flexible wearable antenna system for breast tumor detection

A simple and cost effective imaging device for breast tumor detection based on a flexible and wearable antenna system has been developed by researchers at the Indiana University - Purdue University Indianapolis.

30 Jun 2012